Login to Your Account

Chelsea's Stock Plummets on Shaky Parkinson's Data

By Catherine Shaffer

Thursday, February 3, 2011
Stock in Chelsea Therapeutics International Ltd. tumbled 18.5 percent on Wednesday after the company reported that an interim analysis had found their Phase III (306) trial of Northera (droxidopa) for neurogenic orthostatic hypotension (NOH) in Parkinson's patients to be futile.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription